The introduction of Wegovy in oral tablet form has raised concerns among experts about a potential increase in counterfeit weight-loss medications on the black market. Bhavik Patel, a professor of clinical and bioanalytical chemistry at the University of Brighton, noted that pills are generally easier to replicate than injectable treatments, making them a favored product for illicit manufacturers. “For criminal gangs, pills are their bread and butter,” Patel said.

Data from UK Border Force indicates significant enforcement activity, with 18,316 illegal weight-loss and diabetes-related drugs seized between January 2024 and June 2025. These figures highlight the scope of the problem as authorities contend with the proliferation of counterfeit medicines targeting consumers seeking weight management solutions.

Novo Nordisk, the pharmaceutical company that produces Wegovy, confirmed it is actively addressing the issue through various measures. These include monitoring online platforms for unauthorized sales and collaborating with law enforcement agencies by sharing detailed information about its supply chains. The company emphasized its dedication to increasing legitimate access to the medication for qualified patients while combating fraudulent distribution networks.

The wider availability of Wegovy tablets, designed to facilitate easier administration compared to injections, could inadvertently encourage counterfeit operations to expand. Experts suggest that ongoing vigilance and coordinated responses will be essential to protecting public health as demand for effective weight-loss treatments grows.